Therapeutic categories that exist in trial data but not in any development coverage.
Drug development programs map what's being built. Commercial coverage maps what sells. Neither maps the therapeutic white space - the categories that must exist given observed disease burden, patient population behavior, and pricing structures, but have no product, no named developer, and no established market formation signal. That layer is what Limn surfaces.
Baseline exclusion before publication.
Every report is benchmarked against incumbent planning, orchestration, and network intelligence coverage. The report only contains positions that remain outside the known market envelope.
These platforms are the baseline exclusion set. Every gap here exists outside their coverage envelope.
CNS Adjacency Research: Therapeutic Positions Between Categories
CNS categories are defined by mechanism and indication. The adjacency positions between categories - the comorbidity intersections, the cross-indication mechanisms, the structural positions between neurology and psychiatry - have no named developer coverage. Sixteen gaps identified.
Combination Therapy Structural Gaps: Where the Mechanism Exists But the Product Doesn't
Combination therapy positions that are mechanistically implied by approved monotherapy data but have no named developer and no established development program. Nine gaps identified across oncology combinations, metabolic co-targeting, and immunology overlay structures.
Metabolic Complication Layer: What Diabetes and Obesity Development Data Doesn't Map
The metabolic disease category has seen significant primary development activity. The complication layer - the structural positions that must exist given observed patient population behavior for secondary metabolic conditions - remains unaddressed. Twelve gaps identified.
Pediatric Indication Gap Map: Orphan Categories
Pediatric indication coverage follows adult development programs with a lag that leaves structural positions open. Five gaps identified at the top level in orphan pediatric categories - a starting point for research teams assessing where pediatric white space is structurally unaddressed.
Rare Disease Sub-Category White Space: Q1 2026
Rare disease development coverage systematically misses the sub-category layer - therapeutic positions that exist given orphan disease burden data but have no named developer and no active development program. Twenty-four structural gaps identified, each SCE-validated across independent research sources.
Need a more targeted analysis?
Direct the analysis at your specific market, portfolio, or commercial question.